1. Salivary duct carcinoma: Prospective multicenter study of 61 cases of the Réseau d'Expertise Français des Cancers ORL Rares
- Author
-
Bertrand Baujat, Chloé Bertolus, Olivier Malard, Aude Villepelet, Refcor members, Benjamin Verillaud, François Janot, Sébastien Vergez, Marine Lefevre, Ludovic de Gabory, Olivier Mauvais, Renaud Garrel, CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Pierre et Marie Curie - Paris 6 (UPMC), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Gustave Roussy (IGR), Service d'ORL et chirurgie cervico-faciale, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Bordeaux [Bordeaux], and Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
- Subjects
Adult ,Male ,medicine.medical_specialty ,Gastroenterology ,Disease-Free Survival ,Salivary duct carcinoma ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Tumor stage ,Medicine ,Humans ,Prospective Studies ,030223 otorhinolaryngology ,Lymph node ,salivary duct carcinoma ,Aged ,Neoplasm Staging ,Aged, 80 and over ,business.industry ,Hazard ratio ,Carcinoma ,prognostic factors ,human epidermal growth factor receptor 2 (HER2)/neu ,Middle Aged ,medicine.disease ,Salivary Gland Neoplasms ,Combined Modality Therapy ,targeted therapies ,3. Good health ,Parotid gland ,Androgen receptor ,Survival Rate ,androgen receptors ,medicine.anatomical_structure ,Otorhinolaryngology ,Multicenter study ,030220 oncology & carcinogenesis ,Immunohistochemistry ,Female ,France ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; BACKGROUND:The purposes of this study were to describe the characteristics of a prospective multicenter series of patients with salivary duct carcinoma and to investigate prognostic factors.METHODS:Patients included for salivary duct carcinoma between 2009 and 2016 in the Réseau d'Expertise Français des Cancers ORL Rares (REFCOR) database were selected. Immunohistochemical analyses were performed.RESULTS:Sixty-one patients were included in this study. The primary site was the parotid gland in 90% of the cases. Fifty-seven percent of the tumors were stage IV, 65% of patients had lymph node involvement, and 10% had metastases. Tumors showed androgen receptor (89%) and human epidermal growth factor receptor 2 (HER2)/neu (36%). Ninety-four percent of patients underwent surgery and 86% had postoperative radiotherapy. Six patients were treated with targeted therapies. The 3-year overall survival (OS) was 74% and the 3-year disease-free survival (DFS) was 44%. Tumor stages III to IV reduced DFS (hazard ratio [HR] 4.3; P = .04). The N2/3 class reduced distant metastasis-free survival (HR 7.3; P = .007).CONCLUSION:Salivary duct carcinoma prognosis is poor and is correlated with tumor stage and lymph node classification. Androgen receptor and HER2/neu should be tested as they offer the possibility of targeted therapies.
- Published
- 2019
- Full Text
- View/download PDF